BP11148 PLGA 65:35, Hydroxyl Terminated, IV: 1.0–2.0 dl/g, Mw: 158–410 kDa

PLGA 65:35, Hydroxyl Terminated, IV: 1.0–2.0 dl/g, Mw: 158–410 kDa Description

PLGA 65:35, Hydroxyl Terminated, IV: 1.0–2.0 dl/g, Mw: 158–410 kDa is a copolymer of lactic and glycolic acid with hydroxyl terminal groups, offering controlled hydrolysis in biomedical environments. The defined intrinsic viscosity range reflects its molecular weight distribution, which influences degradation kinetics. These technical specifications ensure suitability for applications requiring precise resorption profiles and reactive chain ends for further chemical modification.

PLGA 65:35, Hydroxyl Terminated, IV: 1.0–2.0 dl/g, Mw: 158–410 kDa Applications

1.         Healthcare
   - Used as a matrix in biodegradable drug delivery systems to achieve steady, controlled release by leveraging predictable hydrolytic degradation.
   - Applied as a scaffold in tissue engineering to provide structural support and facilitate cellular proliferation through predictable resorption.

2.         Industrial
   - Employed as a coating material in medical devices to temporarily protect surfaces by utilising its biocompatible and degradable properties.

PLGA 65:35, Hydroxyl Terminated, IV: 1.0–2.0 dl/g, Mw: 158–410 kDa Packing

The product is packaged in hermetically sealed, moisture-resistant containers, with an inner lining that minimises static and particulate contamination. Storage at low temperatures is recommended to prevent premature degradation. Protective secondary packaging provides additional impact resistance during transit. Customisation options, including labeling and size variation, are available upon request to suit specific handling requirements.

Additional Information

PLGA copolymers are widely studied for their biodegradation behaviour, which is largely influenced by the lactic to glycolic acid ratio and molecular weight distribution. The hydrolytic breakdown of these materials produces metabolically benign by-products, making them suitable for transient implantable devices and regenerative medicine applications.

Understanding the interplay between polymer chain length, terminal functionality, and composition is critical in designing systems for controlled therapeutic release. This material class continues to be refined through advanced synthesis and characterisation techniques, ensuring their applicability in a range of biomedical and industrial processes.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.